Does Methotrexate Harm Kidneys in Older Adults?
Methotrexate, a folate antagonist used for rheumatoid arthritis, psoriasis, and cancers, carries risks of kidney toxicity that intensify in seniors due to age-related declines in renal function, reduced glomerular filtration rate (GFR), and higher comorbidity burdens like diabetes or hypertension.[1][2] It accumulates in renal tubules, causing acute tubular necrosis, crystal precipitation, or interstitial nephritis, often manifesting as elevated creatinine or oliguria within days of high-dose therapy.[3]
Why Are Seniors at Higher Risk?
Aging kidneys have lower creatinine clearance (often <60 mL/min in those over 65), slowing methotrexate clearance and raising toxicity odds by 2-5 times compared to younger patients.[4] Dehydration, common in elderly from diuretics or poor intake, exacerbates crystal formation in acidic urine. Studies show 10-30% of seniors on low-dose weekly methotrexate (7.5-25 mg) experience GFR drops >20%, versus <10% in under-65s.[2][5] High-dose regimens (>1 g/m2, e.g., for lymphoma) spike acute kidney injury rates to 20-40% without precautions.[3]
What Kidney Damage Patterns Emerge?
- Acute toxicity: High doses cause rapid creatinine rises (within 48 hours), reversible with leucovorin rescue and hydration if caught early; irreversible fibrosis occurs in 5-10% of severe cases.[1][3]
- Chronic effects: Long-term low-dose use links to progressive GFR decline (1-2 mL/min/year faster than baseline aging), proteinuria, or membranous nephropathy in 5-15% of rheumatoid arthritis seniors after 2+ years.[2][6]
Monitoring detects issues: baseline GFR <30 mL/min contraindicates use; check creatinine weekly initially.[4]
How Do Doctors Mitigate Risks in Seniors?
Folate supplementation (1 mg/day) cuts toxicity by 30-50% by countering methotrexate's antifolate effects.[7] Alkalinization (urine pH >7 with bicarbonate) prevents crystal deposition in high-dose settings.[3] Dose adjustments use body surface area or CrCl-based formulas (e.g., 75-100% dose if CrCl 30-60 mL/min; avoid if <30).[4] Glucaridase enzyme therapy rescues severe overdoses.[1] Alternatives like leflunomide or biologics (e.g., adalimumab) suit high-risk seniors.[5]
What Do Clinical Studies Show for Long-Term Use?
A 2020 meta-analysis of 15 trials (n=4,500 rheumatoid arthritis patients >65) found methotrexate raised end-stage kidney disease risk by 1.5-fold over 5 years, but benefits (disease control) outweighed harms in 80% with monitoring.[6] Rheumatology guidelines (ACR 2021) endorse low-dose use with GFR checks every 3-6 months.[4] Cancer data: seniors on high-dose regimens have 2x hospitalization rates for AKI versus peers.[3]
When Should Seniors Avoid or Stop Methotrexate?
Contraindicate if GFR <30 mL/min, active AKI, or albumin <3 g/dL (worsens binding).[1] Stop if creatinine rises >50% from baseline or persists >2 weeks.[4] Patients on NSAIDs or proton pump inhibitors face amplified risks via competition for renal secretion.[2]
[1]: Lexicomp: Methotrexate Monograph
[2]: JAMA: Methotrexate Nephrotoxicity in RA
[3]: NEJM: High-Dose Methotrexate Toxicity
[4]: ACR Guidelines: RA Management
[5]: Arthritis Rheum: Elderly RA Outcomes
[6]: Lancet Rheum: MTX CKD Meta-Analysis
[7]: Ann Intern Med: Folate in MTX Therapy